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1. Introduction
  At present, the vascular calcification is considered to be a serious 
cardiovascular complication that contributes to the increased 
morbidity and mortality of patients suffered from diabetes 
mellitus[1,2]. Diabetic vascular calcification can occur in both the 
medial and intimal layers of arterial beds[3]. Vascular calcification 
is an active process affected by many factors and regulated by 
mutiple genes, which is similar to the physiological mineralization 
of skeletal tissues, and vascular smooth muscle cells (VSMCS) 
differentiate into osteoblast like cells is key[4]. A number of factors 
were reported to regulate differentiation of multiple cell types 
among bone and blood vessels, and bone metabolism-related factors 
participate in vascular calcification[5]. osteoprotegerin (OPG)/
receptor activator of NF-毷B ligand (RANKL)/receptor activator of 
NF-毷B ligand (RANK) system is the recently emerging area that 
links between the skeletal, immune and vascular biology[6]. Clinical 
datas have indicated that serum OPG levels is associated with 
vascular calcification in humans, and determination of serum OPG 
has been suggested as a prognostic biomarker of cardiovascular 
disease[7]. 
  In the present investigation, we sought to explore the role of OPG 
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and RANKL expression in the VSMCs in hyperglycemia (blood 
glucose levels >16.6 mmol/L) or high glucose (HG, 25 mmol/L 
D-glucose) conditions. As results, we found that the up-regulation 
of OPG and down-regulation of RANKL were detected in VSMCs 
in streptozotocin (STZ)-induced T1D rat thorocitic arties ex vivo 
and HG-treated VSMCs in vitro. Our studies will provide the 
improved understanding of the mechanism behind diabetic vascular 
calcification.
2. Materials and methods
2.1. Cell line and regents
  Rat aortic smooth muscle cells (A7r5) were purchased from 
Shanghai Cell Bank of Chinese Academy of Sciences (Shanghai, 
China). Rabbit anti-rat OPG and mouse-anti rat RANKL were 
purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA); 
STZ, D-glucose and D-mannitol were from Sigma Aldrich (Sigma 
Aldrich, St Louis, MO, USA). 
2.2. Establishing rat model of T1D
  Male Sprague Dawley (SD) rats, weighing (200依20) g, were 
purchased from the Center of Experimental Animals of Hainan 
Medical College, Haikou, China. All procedures were performed in 
accordance with the Guidelines of the Hainan Council of Animal 
Care and approved by the Animal Use Subcommittee at the Hainan 
Medical College. Rats were made type 1 diabetes (T1D) by single 
intraperitoneally injected STZ (55 mg/kg, Sigma-Aldrich, Shanghai, 
China). Blood glucose was monitored for up to 3 weeks, and only 
the rats with blood glucose levels >16.6 mmol/L were involved in 
the study. At the end of 3 weeks after injection of STZ, rats were 
sacrificed and the thoracic arterial samples were fixed in neutral 
formalin for paraffin-embedded sections.
2.3. Immunohistochemistry (IHC)
  Immunohistochemistrical staining was performed on the sections of 
the rat thoracic arterial samples. The process of IHC was performed 
as stranded protocols. Briefly, After the paraffin sections (5 毺m) 
were deparaffinized and re-hydrated, heat-induced antigen retrieval 
was performed in sodium citrate buffer (pH 6.0, 10 mM) and 
endogenous peroxidases were blocked by incubation in 0.3% H2O2. 
Sections then were incubated with primary antibodies against OPG 
(1:100) and RANKL (1:100) at 4 曟 overnight and non-immune IgG 
was used as negative control. Antigenic sites were localized using a 
SP9000 or SP9003 kit and 3,3’-diaminobenzidine kit (ZSGB-BIO, 
Beijing, China). Samples with a brown color staining in VSMCs 
were considered to display positive expression.
2.4. Quantitative reverse transcription PCR (qRT-PCR)
  Total RNA was extracted with Trizol reagent (Invitrogen, 
Carlsbad, CA, USA). 1 毺g of total RNA was used as template to 
generate the cDNA by oligo(dT18) using Fermentas RT System 
(cat.#K1622, Thermo Scientific, Guangzhou, China). The pairs of 
primers (5’-3’) synthesized by Sangon Biotech Co., Ltd. (Shanghai, 
China) as following, OPG forward TTGGCTGAGTGTTCTGGT, 
r e v e r s e  T T G G G A A A G T G G T A T G C T ;  R A N K L 
f o r w a r d  C A T C G G G T T C C C A T A A A G ,  r e v e r s e 
G A A G C A A AT G T T G G C G TA ;  毬 - a c t i n  f o r w a r d 
C T A T C G G C A A T G A G C G G T T C C ,  r e v e r s e 
TGTGTTGGCATAGAGGTCTTTACG. PCR was conducted using 
the LightCycler480 II instrument (Roche, China) Ltd., Guangzhou, 
China). The total volume was 20 毺L, which include 10 毺L SYBR 
Green I PCR Master Mix (TOYOBO, OSAKA, Japan), 0.4 毺L 
forward primer (10 毺M), 0.4 毺L reverse primer (10 毺M), 2 毺
L cDNA and 7.2 毺L ddH2O. The PCR amplification was as follow, 
after denaturation at 95 曟 for 1 min, 45 PCR cycles were performed 
including 95 曟 for 15 s, 60 曟 for 60 s. The relative abundance of 
target mRNAs were determined from the CT values and plotted as 
the fold change compared with the control groups.
2.5. Western blotting
  Cells were collected and lysed with RIPA lyses buffer (Cat. # 
P0013C, Beyotime Institute of Biotechnology, Jiangsu, China), 
and then proteins were quantified using an Enhanced BCA Protein 
Assay Kit (Cat. #P0010, Beyotime Institute of Biotechnology). Total 
of 40-50 毺g proteins were transferred into PVDF membranes by 
electrophoretic transfer following electrophoretic separation by SDS 
- polyacrylamide gel electrophoresis (SDS-PAGE). The membranes 
were probed with primary antibodies against OPG (1:400, Santa 
Cruz), RANKL (1:400, Santa Cruz), and 毬-actin (1:1 000, Santa 
Cruz) in TBST plus 3% skimmed milk overnight at 4 ℃. After 
three times washed by TBST, the membranes were incubated with 
horseradish peroxidase (HRP)-coupled secondary antibodies for 2 
hour at room temperature. Bands were visualized using enhanced 
chemiluminescence (ECL) reagents (Thermo Fisher, Rockford, IL, 
USA) and analyzed with a BIO-RAD VersaDocTM 5000 MP system 
(Life Science Research, Hercules, CA, USA). Bands of 毬-actin 
were used as loading controls.
2.6. Statistical analyses
  The statistical analyses were carried out by using PRISM Software 
(GraphPad Software, CA, USA). The data were expressed as Mean
依SD. For analysis of differences between two groups, Student’s 
t-test was performed. For multiple groups, ANOVA was carried out 
followed by Student-Newman-Keuls test. The level of statistical 
significance was set at P<0.05.
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3. Results
3.1. Up-regulation of OPG and down-regulation of RANKL 
expression in thoracic arterial samples of streptozotocin-
induced T1D rats
  The rats with blood glucose levels>16.6 mmol/L were considered 
as the hyperglycemia after intraperitoneally injected with STZ. 
Results of immunohistochemistry showed that an obvous increased 
expression of OPG and decreased expression of RANKL was 
detected in VSMCs of thoracic arterial samples of hyperglycemic 
rats when compared with that of normoglycemic rats (Figure 
1). These results indicated that 3-week of hyperglycemia would 
significantly affect OPG and RANKL expression in VSMCs.
Normal glucose                                     High glucose
OPG
RANKL
Figure 1. Expression of OPG and RANKL in tunica media of thoracic 
arties of STZ-induced T1DM (hyperglycemia) rats and normal control 
(normorglycemia) rats. 
Representative photographs of OPG and RANKL protein expression in 
samples of rat thoracic arties. IHC was used to detect OPG and RANKL 
protein expression in tunica media of thoracic arties. For the process of IHC, 
antigens were localized by DAB, tissues were countstained with hematoxylin. 
Non-immune IgGs were used as negative control. Original magnification: 
200×, Bar = 100 毺m. 
3.2. Up-regulation of OPG and down-regulation of RANKL 
in HG-treated cultured VSMCs in vitro
  We then explored the role of HG in the OPG and RANKL 
expression in cultured VSMCs in vitro. The VSMCs were treated 
in NG (normal glucose control), Mtol (osmotic control) and HG 
medium, 48 hours later, cells were used for analysis the OPG and 
RANKL expression. Results of qRT-PCR and western blotting 
showed that HG treatment led to obvious OPG up-regulation and 
RANKL down-regulation (P<0.01, Figure 2A, B) when compared 
with NG and Mtol groups, this results indicated that up-regulation of 
OPG and down-regulation of RANKL was HG-dependent. 
3.3. HG influenced OPG and RANKL expression in VSMCs at 
time-consumed manner
  Consequently, VSMCs were treated with HG (25 mmol/L)for 4, 8, 
12, 24 and 48 hours, and the results showed that with the extension 
of time OPG expression was gradually increased both at mRNA and 
protein level, on the contrary, RANKL expression was gradually 
decreased (Figure 3A, B), which indicated that HG influenced OPG 





















































Figure 2. HG induced OPG expression and suppressed RANKL expression 
in VSMCs in vitro. 
QRT-PCR and western blotting were used to detect OPG (A) and RANKL (B) 
expression in VSMCs maintained in media supplemented with normal glucose 
(NG, 5.5 mmol/L D-glucose), Mitol (Mtol, 25 mmol/L D-mannitol) and high 
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Figure 3. HG influenced OPG and RANKL expression in VSMCs in vitro. 
qRT-PCR and western blotting were used to detect OPG (A) and RANKL 
(B) expression in VSMCs maintained NG (5.5 mmol/L D-glucose, 24 hr) and 
HG (25 mmol/L D-glucose, 4, 8, 12, 24, 48 hr), * P<0.05 vs. NG. ** P<0.01 
vs. NG.
HG (25 mmol/L)
HG (25 mmol/L)HG (25 mmol/L)
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3.4. HG influenced OPG and RANKL expression in VSMCs at 
concerntration-dependent manner
  VSMCs were further treated with HG(48 hours) for 5.5, 12.5, 25 
and 50 mmol/L, as shown in Figure 4A & B, with the increase of 
HG concertration OPG expression was gradually increased both 
at mRNA and protein level, howerer, RANKL expression was 
gradually decreased, which manifested that HG affected OPG 
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Figure 4. HG influenced OPG and RANKL expression in VSMCs in vitro. 
qRT-PCR and western blotting were used to detect OPG (A) and RANKL 
(B) expression in VSMCs maintained in media supplemented with various 
concentration of D-glucose (5.5, 12.5, 25 and 50 mmol/L) for 48 hr, 
**P<0.01 vs. 5.5 mmol/L D-glucose (NG). 
4. Discussion
  Diabetes mellitus (DM) is a chronic disease in which the body 
either can not use or produce the insulin efficiently[7]. Cardiovascular 
disease (CVD) remains the leading cause of death among adults with 
DM, and vascular calcification is a common pathobiological process 
which correlates with increased morbidity and mortality in patients 
with diabetes[6]. Diabetes is a condition most always associated with 
vascular calcification and bone abnormalities[8]. Emerging evidence 
from the last two decades has shown that vascular calcification is 
an active and tightly regulated biological process orchestrated by 
VSMCs adopting an osteoblastic phenotype and that this process 
bears a lot of similarities to physiological bone mineralization. 
In vitro, Chen et al have shown that VSMCs incubated with high 
concentration of glucose led to an increased expression of the 
osteoblast transcription factor core binding factor alpha subunit 
1 (Cbfa1) and the relative gene expression of ALP and OCN, 
acceleration the VSMCs calcification[9]. Al-Aly et al also found that 
Ldlr-/- mice fed high fat diet developed hyperglycemia, dyslipidemia 
and aortic calcification primarily in the tunica media with activation 
of BMP-2/Msx2-Wnt pathway[10]. Accordingly, the present 
results suggested that the increased diabetic vascular calcification 
was partially due to the direct effects of hyperglycemia on the 
transforming of the VSMCs to osteoblast-like phenotype. However, 
the mechanism of phenotypic change of VSMCs to osteoblast-like 
cells VSMCs is not understood well, specifically in diabetic high-
glucose conditions.
  RANKL, a 316-amino acid transmembrane protein that is highly 
expressed by T cells in lymphoid tissue and osteoblast /stromal 
cells in trabecular bone[11-15], binds and activates its RANK, a 616-
amino acid transmembrane receptor, which is mainly expressed 
by osteoclasts and their precusor[16]. RANKL actions are inhibited 
by OPG, a member of a tumor necrosis factor (TNF) superfamily 
of proteins that is secreted by osteoblasts. OPG competes with 
RANK and functions as a decoy receptor to bind to RANKL with 
high affinity for prevention RANKL/RANK interactions[17,18]. The 
signaling pathway of RANK/RANKL / OPG has been suggested 
as the link between vascular and bone metabolism[19,20]. OPG-/- 
mice not only exhibited a decrease in total bone density but also 
developed the medial calcification of renal and aortic arteries[21]. 
Recent outcome studies have indicated that plasma OPG is a strong 
predictor of cardiovascular disease[22-24]. The cellular source of OPG 
system in vasculature is mainly ascribe to the endothelia cells[25] 
and VSMCs[26,27]. Of much interest, in this study we observed an 
up-regulation of OPG and down-regulation of RANKL expression 
in the samples both the thoracic VSMCs of STZ-induced T1D 
and HG-treated VSMCs. Moreover, the results of the experiments 
conducted in vitro revealed that HG induced the increased expression 
of OPG and decreased expression of RANKL in not only glucose 
concentration - dependent but also time - consumption manners.  
  Although complex mechanisms are involved in the initiation and 
progression of vascular calcification, a central part of which is the 
phenotypic transition of VSMCs to osteoblast-like cells. The present 
study demonstrated that hyperglycemia/HG treatment could induce 
OPG expression and supress RANKL expression, suggesting that 
RANK/RANKL/OPG system plays a pivotal role in HG-stimulated 
VSMCs and providing an understanding of molecular and celluar 
mechanism involved in diabetic vascular calcification.
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